Hepatocellular carcinoma

The Lancet

Volumn 379, Issue 9822, 2012, Pages 1245-1255

  Forner, Alejandro ^a,b   Llovet, Josep M ^a,b,c,d   Bruix, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; AXITINIB; BETA CATENIN; BEVACIZUMAB; BRIVANIB; CAPECITABINE; DOVITINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; LINIFANIB; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAPATUMUMAB; MICRORNA; NINTEDANIB; OXALIPLATIN; PROTEIN P53; RAMUCIRUMAB; SCATTER FACTOR; SOMATOMEDIN RECEPTOR; SORAFENIB; TIVANTINIB; UVOMORULIN; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

ABLATION THERAPY; ALCOHOL CONSUMPTION; CANCER CLASSIFICATION; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CELL SURVIVAL; CHEMOEMBOLIZATION; CHROMOSOME 11Q; CHROMOSOME 6P; CONFERENCE PAPER; DIABETES CONTROL; DISEASE SURVEILLANCE; DRUG EXPOSURE; ECHOGRAPHY; GASTROINTESTINAL DISEASE; GENE MUTATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; SKIN DISEASE; TUMOR ABLATION;

EID: 84859212951     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61347-0     Document Type: Conference Paper

References (127)

1. J Ferlay, HR Shin, F Bray, D Forman, C Mathers, DM Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. W Alazawi, M Cunningham, J Dearden, GR Foster Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection Aliment Pharmacol Ther 32 2010 344 355
3. JM Llovet, A Burroughs, J Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
4. M Sherman Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis Semin Liver Dis 30 2010 3 16
5. C Bosetti, F Levi, P Boffetta, F Lucchini, E Negri, C La Vecchia Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004 Hepatology 48 2008 137 145
6. HB El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
7. D Qiu, K Katanoda, T Marugame, T Sobue A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004) Int J Cancer 124 2009 443 448
8. Y Tanaka, F Kurbanov, S Mano et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality Gastroenterology 130 2006 703 714
9. GL Davis, MJ Alter, H El-Serag, T Poynard, LW Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
10. HB El-Serag, T Tran, JE Everhart Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma Gastroenterology 126 2004 460 468
11. EE Calle, C Rodriguez, K Walker-Thurmond, MJ Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults N Engl J Med 348 2003 1625 1638
12. JA Marrero, RJ Fontana, S Fu, HS Conjeevaram, GL Su, AS Lok Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma J Hepatol 42 2005 218 224
13. F Bravi, C Bosetti, A Tavani, C La Vecchia Coffee drinking and hepatocellular carcinoma: an update Hepatology 50 2009 1317 1318
14. RP Beasley, LY Hwang, CC Lin, CS Chien Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan Lancet 318 1981 1129 1133
15. CJ Chen, HI Yang, J Su et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
16. C Brechot, V Thiers, D Kremsdorf, B Nalpas, S Pol, P Paterlini-Brechot Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 34 2001 194 203
17. JD Chen, HI Yang, UH Iloeje et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death Gastroenterology 138 2010 1747 1754
18. MH Chang, CJ Chen, MS Lai for the Taiwan Childhood Hepatoma Study Group Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children N Engl J Med 336 1997 1855 1859
19. GV Papatheodoridis, P Lampertico, S Manolakopoulos, A Lok Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
20. G Fattovich, T Stroffolini, I Zagni, F Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 2004 S35 S50
21. S Bruno, T Stroffolini, M Colombo et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
22. AK Singal, A Singh, S Jaganmohan et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis Clin Gastroenterol Hepatol 8 2010 192 199
23. H Yoshida, Y Shiratori, M Moriyama for the IHIT Study Group Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131 1999 174 181
24. Y Imai, S Kawata, S Tamura et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99
25. AM Di Bisceglie, ML Shiffman, GT Everson et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
26. J Bruix, T Poynard, M Colombo et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C Gastroenterology 140 2011 1990 1999
27. DC MacDonald, M Nelson, M Bower, T Powles Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era World J Gastroenterol 14 2008 1657 1663
28. PA Farazi, RA DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 2006 674 687
29. A Villanueva, P Newell, DY Chiang, SL Friedman, JM Llovet Genomics and signaling pathways in hepatocellular carcinoma Semin Liver Dis 27 2007 55 76
30. J Ji, J Shi, A Budhu et al. MicroRNA expression, survival, and response to interferon in liver cancer N Engl J Med 361 2009 1437 1447
31. S Toffanin, Y Hoshida, A Lachenmayer et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a Gastroenterology 140 2011 1618 1628
32. A Villanueva, DY Chiang, P Newell et al. Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
33. F Sahin, R Kannangai, O Adegbola, J Wang, G Su, M Torbenson mTOR and P70 S6 kinase expression in primary liver neoplasms Clin Cancer Res 10 2004 8421 8425
34. M Fernandez, D Semela, J Bruix, I Colle, M Pinzani, J Bosch Angiogenesis in liver disease J Hepatol 50 2009 604 620
35. Y Hoshida, SM Nijman, M Kobayashi et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
36. Y Hoshida, A Villanueva, M Kobayashi et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 2008 1995 2004
37. A Villanueva, Y Hoshida, C Battiston et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma Gastroenterology 140 2011 1501 1512
38. JM Croswell, DF Ransohoff, BS Kramer Principles of cancer screening: lessons from history and study design issues Semin Oncol 37 2010 202 215
39. BH Zhang, BH Yang, ZY Tang Randomized controlled trial of screening for hepatocellular carcinoma J Cancer Res Clin Oncol 130 2004 417 422
40. H Poustchi, G Farrell, S Strasser, A Lee, G McCaughan, J George Feasibility of conducting a randomised control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 54 2011 1998 2004
41. FP Sarasin, E Giostra, A Hadengue Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis Am J Med 101 1996 422 434
42. MR Arguedas, VK Chen, MA Eloubeidi, MB Fallon Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis Am J Gastroenterol 98 2003 679 690
43. J Bruix, M Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
44. A Singal, ML Volk, A Waljee et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis Aliment Pharmacol Ther 30 2009 37 47
45. F Trevisani, PE D'Intino, AM Morselli-Labate et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status J Hepatol 34 2001 570 575
46. JA Marrero, Z Feng, Y Wang et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma Gastroenterology 137 2009 110 118
47. AS Lok, RK Sterling, JE Everhart et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma Gastroenterology 138 2010 493 502
48. B Zhang, B Yang Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer J Med Screen 6 1999 108 110
49. J-C Trinchet, C Chaffaut, V Bourcier for the Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH) Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities Hepatology 54 2011 1987 1997
50. V Santi, F Trevisani, A Gramenzi et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival J Hepatol 53 2010 291 297
51. HG Welch, WC Black Overdiagnosis in cancer J Natl Cancer Inst 102 2010 605 613
52. EA Pomfret, K Washburn, C Wald et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States Liver Transpl 16 2010 262 278
53. A Colli, M Fraquelli, G Casazza et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review Am J Gastroenterol 101 2006 513 523
54. A Forner, R Vilana, C Ayuso et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104
55. A Sangiovanni, MA Manini, M Iavarone et al. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis Gut 59 2010 638 644
56. KT Khalili, TK Kim, HJ Jang et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization J Hepatol 54 2011 723 728
57. LD Chen, HX Xu, XY Xie et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound Eur Radiol 20 2010 743 753
58. R Vilana, A Forner, L Bianchi et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound Hepatology 51 2010 2020 2029
59. JM Llovet, Y Chen, E Wurmbach et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis Gastroenterology 131 2006 1758 1767
60. L Di Tommaso, A Destro, V Fabbris et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma Hepatology 53 2011 1549 1557
61. A Forner, ME Reig, C Rodriguez de Lope, J Bruix Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 2010 61 74
62. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators Hepatology 28 1998 751 755
63. R Tateishi, H Yoshida, S Shiina et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients Gut 54 2005 419 425
64. M Kudo, H Chung, Y Osaki Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) J Gastroenterol 38 2003 207 215
65. CY Hsu, YH Huang, CY Hsia et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System J Hepatol 53 2010 108 117
66. JN Vauthey, GY Lauwers, NF Esnaola et al. Simplified staging for hepatocellular carcinoma J Clin Oncol 20 2002 1527 1536
67. JM Llovet, C Bru, J Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
68. JM Llovet, J Bustamante, A Castells et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 1999 62 67
69. G Cabibbo, M Enea, M Attanasio, J Bruix, A Craxi, C Camma A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 2010 1274 1283
70. JM Llovet, AM Di Bisceglie, J Bruix et al. Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
71. JM Llovet, J Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
72. J Llovet, S Ricci, V Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
73. A-L Cheng, Y-K Kang, Z Chen et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
74. LA Dawson The evolving role of radiation therapy in hepatocellular carcinoma Cancer Radiother 12 2008 96 101
75. KH Han, J Seong, JK Kim, SH Ahn, Y Lee do, CY Chon Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis Cancer 113 2008 995 1003
76. P Hilgard, M Hamami, AE Fouly et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
77. R Salem, RJ Lewandowski, MF Mulcahy et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
78. B Sangro, L Carpanese, R Cianni on behalf of the European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation Hepatology 54 2011 868 878
79. RN Pugh, IM Murray-Lyon, JL Dawson, MC Pietroni, R Williams Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
80. G D'Amico, G Garcia-Tsao, L Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231
81. JM Llovet, M Schwartz, V Mazzaferro Resection and liver transplantation for hepatocellular carcinoma Semin Liver Dis 25 2005 181 200
82. JM Llovet, J Fuster, J Bruix Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation Hepatology 30 1999 1434 1440
83. T Ishizawa, K Hasegawa, T Aoki et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma Gastroenterology 134 2008 1908 1916
84. S Shiina, T Teratani, S Obi et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma Gastroenterology 129 2005 122 130
85. K Takayasu, S Arii, I Ikai et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients Gastroenterology 131 2006 461 469
86. Bargellini I, Sacco R, Bozzi E, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol (published online April 3, 2011). DOI:10.1016/j.ejrad.2011.03.046.
87. M Varela, MI Real, M Burrel et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
88. H Imamura, Y Matsuyama, E Tanaka et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J Hepatol 38 2003 200 207
89. S Breitenstein, D Dimitroulis, H Petrowsky, MA Puhan, B Müllhaupt, P-A Clavien Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis Br J Surg 96 2009 975 981
90. Y-C Shen, C Hsu, L-T Chen, C-C Cheng, F-C Hu, A-L Cheng Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach J Hepatol 52 2010 889 894
91. Y Miyake, A Takaki, Y Iwasaki, K Yamamoto Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma J Viral Hepat 17 2010 287 292
92. M Sala, J Fuster, JM Llovet et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation Liver Transpl 10 2004 1294 1300
93. V Mazzaferro, E Regalia, R Doci et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
94. H Bismuth, L Chiche, R Adam, D Castaing, T Diamond, A Dennison Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis Ann Surg 218 1993 145 151
95. S Jonas, WO Bechstein, T Steinmuller et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis Hepatology 33 2001 1080 1086
96. J Bruix, M Sherman, JM Llovet for the EASL panel of experts on HCC Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference J Hepatol 35 2001 421 430
97. Clavien P-A, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A, on behalf of the OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (published online Nov 1, 2011). DOI:10.1016/S1470-2045(11)70175-9.
98. RB Freeman, EB Edwards, AM Harper Waiting list removal rates among patients with chronic and malignant liver diseases Am J Transplant 6 2006 1416 1421
99. JM Llovet, X Mas, JJ Aponte et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation Gut 50 2002 123 128
100. PS Kamath, RH Wiesner, M Malinchoc et al. A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
101. FY Yao, L Ferrell, NM Bass et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 2001 1394 1403
102. SG Lee, S Hwang, DB Moon et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center Liver Transpl 14 2008 935 945
103. JI Herrero, B Sangro, F Pardo et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria Liver Transpl 14 2008 272 278
104. V Mazzaferro, JM Llovet, R Miceli on behalf of the Metroticket Investigator Study Group Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 2009 35 43
105. V Mazzaferro, YS Chun, RT Poon et al. Liver transplantation for hepatocellular carcinoma Ann Surg Oncol 15 2008 1001 1007
106. ML Volk, S Vijan, JA Marrero A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria Am J Transplant 8 2008 839 846
107. AA Schnitzbauer, C Zuelke, C Graeb et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma BMC Cancer 10 2010 190
108. R Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
109. G Germani, M Pleguezuelo, K Gurusamy, T Meyer, G Isgro, AK Burroughs Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis J Hepatol 52 2010 380 388
110. YK Cho, JK Kim, MY Kim, H Rhim, JK Han Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies Hepatology 49 2009 453 459
111. A Orlando, G Leandro, M Olivo, A Andriulli, M Cottone Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials Am J Gastroenterol 104 2009 514 524
112. R Tateishi, S Shiina, T Teratani et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases Cancer 103 2005 1201 1209
113. MS Chen, JQ Li, Y Zheng et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma Ann Surg 243 2006 321 328
114. GT Huang, PH Lee, YM Tsang et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study Ann Surg 242 2005 36 42
115. J Huang, L Yan, Z Cheng et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann Surg 252 2010 903 912
116. JM Llovet, MI Real, X Montaña for the Barcelona Clínic Liver Cancer Group Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
117. CM Lo, H Ngan, WK Tso et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
118. RS Oliveri, J Wetterslev, C Gluud Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma Cochrane Database Syst Rev 3 2011 CD004787
119. G Pelletier, A Roche, O Ink et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 11 1990 181 184
120. M Doffoel, F Bonnetain, O Bouche et al. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402) Eur J Cancer 44 2008 528 538
121. DY Lin, YF Liaw, TY Lee, CM Lai Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial Gastroenterology 94 1988 453 456
122. J Lammer, K Malagari, T Vogl et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
123. J Raoul, B Sangro, A Forner et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
124. JA Marrero, R Lencioni, M Kudo, F Nakajima, AP Cihon, A Venook Global Investigation of therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction J Clin Oncol 29 suppl 2011 4001 (abstr).
125. AB Benson, TA Abrams, E Ben-Josef et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 2009 350 391
126. P Therasse, SG Arbuck, EA Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
127. A Cheng, Y Kang, D Lin et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) J Clin Oncol 29 suppl 2011 4000 (abstr).